Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the ...

Merck delivered a strong Q4 double beat, with robust pipeline momentum and a healthy new launch cycle. Read more on the ...

For full-year 2025, Merck reported worldwide sales of $65B, up 1% Y/Y, or 2% excluding FX, while adjusted EPS totaled $8.98.

Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of $2.01 per ...

Merck shares began peeling back in early 2024, mostly on concerns about looming patent expirations for its breadwinning drug. The trading crowd changed its collective mind a couple months ago, sending ...

We came across a bullish thesis on Merck & Co., Inc. on R. Dennis’s Substack’s Substack by OppCost. In this article, we will summarize the bulls’ thesis on MRK. Merck & Co., Inc.’s share was trading ...

Merck & Co shares are trading up 1.19% at $107.25 at the time of this writing on Thursday morning. About Merck & Co. Merck makes pharmaceutical products to treat several condition ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the ...

It was revealed in a recent SEC filing that Chirfi Guindo, Chief Marketing Officer at Merck & Co (NYSE: MRK) made a ...

Merck will report its earnings on Tuesday, offering insights into how its agreement to lower the price of its diabetes drug ...